TY - JOUR AU - Wéber, András AU - Vignat, Jerome AU - Shah, Richa AU - Morgan, Eileen AU - Laversanne, Mathieu AU - Nagy, Péter AU - Kenessey, István AU - Znaor, Ariana TI - Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. JF - WORLD JOURNAL OF UROLOGY J2 - WORLD J UROL VL - 42 PY - 2024 IS - 1 PG - 10 SN - 0724-4983 DO - 10.1007/s00345-024-04949-8 UR - https://m2.mtmt.hu/api/publication/34805400 ID - 34805400 AB - In 2020, bladder cancer (BC) was the seventh most prevalent cancer in the world, with 5-year prevalence of more than 1.7 million cases. Due to the main risk factors-smoking and chemical exposures-associated with BC, it is considered a largely preventable and avoidable cancer. An overview of BC mortality can allow an insight not only into the prevalence of global risk factors, but also into the varying efficiency of healthcare systems worldwide. For this purpose, this study analyzes the national mortality estimates for 2020 and projected future trends up to 2040.Age-standardized mortality rates per 100,000 person-years of BC for 185 countries by sex were obtained from the GLOBOCAN 2020 database, operated by the International Agency for Research on Cancer (IARC). Mortality rates were stratified according to sex and Human Development Index (HDI). BC deaths were projected up to 2040 on the basis of demographic changes, alongside different scenarios of annually increasing, stable or decreasing mortality rates from the baseline year of 2020.In 2020, nearly three times more men died from BC than women, with more than 210,000 deaths in both sexes combined, worldwide. Regardless of gender, more than half of the total BC deaths were from countries with a very high HDI. According to our projections, while the number of deaths for men can only increase up to 54% (from 159 to around 163-245 thousand), for women it is projected to increase two- to three-fold (from 50 to around 119-176 thousand) by 2040. The burden of BC mortality in countries with a very high HDI versus high HDI appears to converge by 2040 for both sexes.Opposite mortality trends by gender highlight the urgent need for immediate interventions to expand anti-tobacco strategies, especially for women. The implementation of more strict occupational health and safety regulations could also prevent exposures associated with BC. Improving the ability to detect BC earlier and access to treatment can have a significant positive impact on reducing mortality rates, minimizing economic costs, and enhancing the quality of life for patients. LA - English DB - MTMT ER - TY - JOUR AU - Panagaki, Theodora AU - Janickova, Lucia AU - Petrovic, Dunja AU - Zuhra, Karim AU - Ditrói, Tamás AU - Jurányi, Eszter Petra AU - Bremer, Olivier AU - Ascenção, Kelly AU - Philipp, Thilo M AU - Nagy, Péter AU - Filipovic, Milos R AU - Szabo, Csaba TI - Neurobehavioral dysfunction in a mouse model of Down syndrome. upregulation of cystathionine β-synthase, H2S overproduction, altered protein persulfidation, synaptic dysfunction, endoplasmic reticulum stress, and autophagy TS - upregulation of cystathionine β-synthase, H2S overproduction, altered protein persulfidation, synaptic dysfunction, endoplasmic reticulum stress, and autophagy JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE PY - 2024 SN - 2509-2715 DO - 10.1007/s11357-024-01146-8 UR - https://m2.mtmt.hu/api/publication/34778874 ID - 34778874 N1 - Funding Agency and Grant Number: Fondation Jrme Lejeune Funding text: The editorial assistance of Dr. Anita Marton is appreciated. AB - Down syndrome (DS) is a genetic condition where the person is born with an extra chromosome 21. DS is associated with accelerated aging; people with DS are prone to age-related neurological conditions including an early-onset Alzheimer's disease. Using the Dp(17)3Yey/ + mice, which overexpresses a portion of mouse chromosome 17, which encodes for the transsulfuration enzyme cystathionine β-synthase (CBS), we investigated the functional role of the CBS/hydrogen sulfide (H2S) pathway in the pathogenesis of neurobehavioral dysfunction in DS. The data demonstrate that CBS is higher in the brain of the DS mice than in the brain of wild-type mice, with primary localization in astrocytes. DS mice exhibited impaired recognition memory and spatial learning, loss of synaptosomal function, endoplasmic reticulum stress, and autophagy. Treatment of mice with aminooxyacetate, a prototypical CBS inhibitor, improved neurobehavioral function, reduced the degree of reactive gliosis in the DS brain, increased the ability of the synaptosomes to generate ATP, and reduced endoplasmic reticulum stress. H2S levels in the brain of DS mice were higher than in wild-type mice, but, unexpectedly, protein persulfidation was decreased. Many of the above alterations were more pronounced in the female DS mice. There was a significant dysregulation of metabolism in the brain of DS mice, which affected amino acid, carbohydrate, lipid, endocannabinoid, and nucleotide metabolites; some of these alterations were reversed by treatment of the mice with the CBS inhibitor. Thus, the CBS/H2S pathway contributes to the pathogenesis of neurological dysfunction in DS in the current animal model. LA - English DB - MTMT ER - TY - JOUR AU - Galambos, Klaudia AU - Czikora, Ágnes AU - Erdélyi, Katalin AU - Nagy, Péter TI - Versatile roles of cysteine persulfides in tumor biology. JF - CURRENT OPINION IN CHEMICAL BIOLOGY J2 - CURR OPIN CHEM BIOL VL - 79 PY - 2024 SP - 102440 SN - 1367-5931 DO - 10.1016/j.cbpa.2024.102440 UR - https://m2.mtmt.hu/api/publication/34720278 ID - 34720278 AB - Rewiring the transsulfuration pathway is recognized as a rapid adaptive metabolic response to environmental conditions in cancer cells to support their increased cysteine demand and to produce Reactive Sulfur Species (RSS) including hydrogen sulfide (H2S) and cysteine persulfide. This can directly (via RSS) or indirectly (by supplying Cys) trigger chemical or enzyme catalyzed persulfidation on critical protein cysteine residues to protect them from oxidative damage and to orchestrate protein functions, and thereby contribute to cancer cell plasticity. In this review key aspects of persulfide-mediated biological processes are highlighted and critically discussed in relation to cancer cell survival, bioenergetics, proliferation as well as in tumor angiogenesis, adaptation to hypoxia and oxidative stress, and regulation of epithelial to mesenchymal transition. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Gergő Attila AU - Vokó, Zoltán AU - Sütő, Gábor AU - Rokszin, György Aurél AU - Nagy, Dávid AU - Surján, György AU - Surján, Orsolya AU - Nagy, Péter AU - Kenessey, István AU - Wéber, András AU - Pálosi, Mihály AU - Müller, Cecília AU - Kásler, Miklós AU - Wittmann, István AU - Kiss, Zoltán TI - Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study) JF - BMJ OPEN DIABETES RESEARCH & CARE J2 - BMJ OPEN DIAB RES CA VL - 12 PY - 2024 IS - 1 PG - 10 SN - 2052-4897 DO - 10.1136/bmjdrc-2023-003777 UR - https://m2.mtmt.hu/api/publication/34538356 ID - 34538356 N1 - * Megosztott szerzőség AB - Introduction Type 2 diabetes mellitus is a risk factor for severe COVID-19 infection and is associated with increased risk of complications. The present study aimed to investigate effectiveness and persistence of different COVID vaccines in persons with or without diabetes during the Delta wave in Hungary.Research design and methods Data sources were the national COVID-19 registry data from the National Public Health Center and the National Health Insurance Fund on the total Hungarian population. The adjusted incidence rate ratios and corresponding 95% CIs were derived from a mixed-effect negative binomial regression model.Results A population of 672 240 cases with type 2 diabetes and a control group of 2 974 102 non-diabetic persons free from chronic diseases participated. Unvaccinated elderly persons with diabetes had 2.68 (95% CI 2.47 to 2.91) times higher COVID-19-related mortality rate as the ‘healthy’ controls. Primary immunization effectively equalized the risk of COVID-19 mortality between the two groups. Vaccine effectiveness declined over time, but the booster restored the effectiveness against mortality to over 90%. The adjusted vaccine effectiveness of the primary Pfizer-BioNTech against infection in the 14–120 days of postvaccination period was 71.6 (95% CI 66.3 to 76.1)% in patients aged 65–100 years with type 2 diabetes and 64.52 (95% CI 59.2 to 69.2)% in the controls. Overall, the effectiveness tended to be higher in individuals with diabetes than in controls. The booster vaccines could restore vaccine effectiveness to over 80% concerning risk of infection (eg, patients with diabetes aged 65–100 years: 89.1 (88.1–89.9)% with Pfizer-on-Pfizer, controls 65–100 years old: 86.9 (85.8–88.0)% with Pfizer-on-Pfizer, or patients with diabetes aged 65–100 years: 88.3 (87.2–89.2)% with Pfizer-on-Sinopharm, controls 65–100 years old: 87.8 (86.8–88.7)% with Pfizer-on-Sinopharm).Conclusions Our data suggest that people with type 2 diabetes may have even higher health gain when getting vaccinated as compared with non-diabetic persons, eliminating the marked, COVID-19-related excess risk of this population. Boosters could restore protection.Data are available upon reasonable request. LA - English DB - MTMT ER - TY - JOUR AU - Boutros, Michael AU - Baumann, Michael AU - Bigas, Anna AU - Chaabane, Linda AU - Guérin, Julien AU - Habermann, Jens K AU - Jobard, Aurélien AU - Pelicci, Pier Giuseppe AU - Stegle, Oliver AU - Tonon, Giovanni AU - Valencia, Alfonso AU - Winkler, Eva C AU - Blanc, Patricia AU - De Maria, Ruggero AU - Medema, Rene H AU - Nagy, Péter AU - Tabernero, Josep AU - Solary, Eric TI - UNCAN.eu: Toward a European Federated Cancer Research Data Hub JF - CANCER DISCOVERY J2 - CANCER DISCOV VL - 14 PY - 2024 IS - 1 SP - 30 EP - 35 PG - 6 SN - 2159-8274 DO - 10.1158/2159-8290.CD-23-1111 UR - https://m2.mtmt.hu/api/publication/34523883 ID - 34523883 AB - To enable a collective effort that generates a new level of UNderstanding CANcer (UNCAN.eu) [Cancer Discov (2022) 12 (11): OF1], the European Union supports the creation of a sustainable platform that connects cancer research across Member States. A workshop hosted in Heidelberg gathered European cancer experts to identify ongoing initiatives that may contribute to building this platform and discuss the governance and long-term evolution of a European Federated Cancer Data Hub. LA - English DB - MTMT ER - TY - JOUR AU - Ringborg, Ulrik AU - von Braun, Joachim AU - Celis, Julio AU - Baumann, Michael AU - Berns, Anton AU - Eggermont, Alexander AU - Heard, Edith AU - Heitor, Manuel AU - Chandy, Mammen AU - Chen, Chien-Jen AU - Costa, Alberto AU - De Lorenzo, Francesco AU - De Robertis, Edward M AU - Dubee, Frederick Charles AU - Ernberg, Ingemar AU - Gabriel, Mariya AU - Helland, Åslaug AU - Henrique, Rui AU - Jönsson, Bengt AU - Kallioniemi, Olli AU - Korbel, Jan AU - Krause, Mechthild AU - Lowy, Douglas R AU - Michielin, Olivier AU - Nagy, Péter AU - Oberst, Simon AU - Paglia, Vincenzo AU - Parker, M Iqbal AU - Ryan, Kevin AU - Sawyers, Charles L AU - Schüz, Joachim AU - Silkaitis, Katherine AU - Solary, Eric AU - Thomas, David AU - Turkson, Peter AU - Weiderpass, Elisabete AU - Yang, Huanming TI - Strategies to decrease inequalities in cancer therapeutics, care and prevention. JF - MOLECULAR ONCOLOGY J2 - MOL ONCOL VL - 18 PY - 2024 IS - 2 SP - 245 EP - 279 PG - 35 SN - 1574-7891 DO - 10.1002/1878-0261.13575 UR - https://m2.mtmt.hu/api/publication/34450816 ID - 34450816 N1 - European Academy of Cancer Sciences, Stockholm, Sweden Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden Pontifical Academy of Sciences, Vatican City, Italy Bonn University, Germany Danish Cancer Institute, Copenhagen, Denmark German Cancer Research Center, Heidelberg, Germany The Netherlands Cancer Institute, Amsterdam, Netherlands University Medical Center Utrecht & Princess Máxima Center for Pediatric Oncology, Netherlands European Molecular Biology Laboratory, Heidelberg, Germany Centre for Innovation, Tech. & Policy Research, IN+@IS Tecnico, University of Lisbon, Portugal Tata Medical Center, Kolkata, India Christian Medical College and Hospital, Vellore, India Academia Sinica, Taipei, Taiwan European Commission, Cabinet of Commissioner Stella Kyriakides, Brussels, Belgium European Cancer Patient Coalition, Brussels, Belgium University of California, Los Angeles, CA, United States Beijing Genomics Institute (BGI), Helsinki, Finland Karolinska Institutet, Stockholm, Sweden European Commissioner for Innovation, Research, Culture, Education and Youth, Brussels, Belgium Division for Cancer Medicine, Oslo University Hospital, Norway Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Portugal Stockholm School of Economics, Sweden Science for Life Laboratory, Stockholm, Sweden Carl Gustav Carus University Hospital and Faculty of Medicine, TU Dresden, Germany National Cancer Institute, Bethesda, MD, United States CHUV Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary Department of Anatomy and Histology, HUN-REN–UVMB Laboratory of Redox Biology Research Group, University of Veterinary Medicine, Budapest, Hungary Chemistry Institute, University of Debrecen, Hungary Organisation of European Cancer Institutes, Brussels, Belgium Pontifical Academy for Life, Rome, Italy University of Cape Town and African Academy of Sciences, South Africa Cancer Research UK Scotland Institute, Glasgow, United Kingdom Memorial Sloan Kettering Cancer Center, New York, NY, United States International Agency for Research on Cancer, Lyon, France World Health Organisation, Lyon, France Gustave Roussy Cancer Campus Grand Paris, Villejuif, France Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Sydney, Australia Beijing Genomics Institute (BGI), Shenzhen, China Cited By :1 Export Date: 4 April 2024 Correspondence Address: Ringborg, U.; European Academy of Cancer Sciences, Visionsvägen 56, Solna, Sweden; email: ulrik.ringborg@ki.se AB - Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic, technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth of Personalized/Precision Cancer Medicine (PCM). Initiatives like the US-Cancer Moonshot and the EU-Mission on Cancer and Europe´s Beating Cancer Plan are initiated to boost cancer prevention and therapeutics/care innovation and to mitigate present inequalities. The conference organised by the Pontifical Academy of Sciences in collaboration with the European Academy of Cancer Sciences discussed the inequality problem, dependent on the economic status of a country, the increasing demands for infrastructure supportive of innovative research and its implementation in healthcare and prevention programs. Establishing translational research and a coherent cancer research continuum is still a challenge. Research has to cover the entire continuum from basic to outcomes research for clinical and prevention components. Comprehensive Cancer Centres (CCCs) are of critical importance for integrating research innovations to preclinical and early clinical research, as for ensuring state-of-the-art patient care within healthcare systems. International collaborative networks between CCCs are necessary to reach the critical mass of infrastructures and patients for PCM research, and for introducing prevention modalities and new treatments effectively. Outcomes and health economics research are required to assess the cost-effectiveness of new interventions, currently a missing element in the research portfolio. Data sharing and critical mass are essential for innovative research to develop PCM. Despite advances in cancer research, cancer incidence and prevalence is growing. Making cancer research infrastructures accessible for all patients, considering the increasing inequalities, requires science policy actions incentivising research aimed at prevention and cancer therapeutics/care with an increased focus on patients´ needs and cost-effective healthcare. LA - English DB - MTMT ER - TY - JOUR AU - Kenessey, István AU - Patócs, Attila Balázs AU - Dobozi, Mária AU - Nagy, Péter AU - Polgár, Csaba TI - A központi idegrendszer primer rosszindulatú daganatainak epidemiológiája és etiológiája JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 67 PY - 2023 IS - 4 SP - 279 EP - 287 PG - 9 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/34450801 ID - 34450801 N1 - English Abstract; Journal Article AB - The occurrence of central nervous system malignancies is relatively low; however, these tumors exhibit poor prognosis and a high mortality rate. On epidemiological grounds, Hungary was placed in the last third among European countries: in the last decade annually 750 to 1000 new cases were diagnosed and the number of deaths was between 550 and 690, without any apparent trends. Age distribution analyses revealed childhood peak and a higher peak at around 65 years of age. Histologically, heterogeneity was apparent, but at least half of the cases were glioblastomas. The exact etiology of adulthood brain tumors is mostly unknown. Among environmental exposures the effect of ionizing radiation was confirmed, the identification of other potential risk factors requires further examinations. 7-10 percent of brain tumors were hereditary tumor syndromes (Li-Fraumeni, neurofibromatosis, sclerosis tuberosa, von Hippel-Lindau, Gorlin- Goltz). Therefore, genetic testing is recommended for families where the diagnosis of brain tumor is suspected. LA - Hungarian DB - MTMT ER - TY - GEN AU - Nagy, Péter TI - Az Országos Onkológiai Intézet tudományos platformjának fejlődése és OECI akkreditációban való szerepe PY - 2023 UR - https://m2.mtmt.hu/api/publication/34430735 ID - 34430735 LA - Hungarian DB - MTMT ER - TY - GEN AU - Nagy, Péter TI - A transszulfurációs utak és metabolitjaik tumorspecifikus szerepei tumorprogresszióban PY - 2023 UR - https://m2.mtmt.hu/api/publication/34430301 ID - 34430301 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Polivka, Lőrinc AU - Vályi-Nagy, István AU - Szekanecz, Zoltán AU - Bogos, Krisztina AU - Vágó, Hajnalka AU - Kamondi, Anita AU - Fekete, Ferenc AU - Szlavik, Janos AU - Surjan, György AU - Surjan, Orsolya AU - Nagy, Péter AU - Schaff, Zsuzsa AU - Kiss, Zoltán AU - Müller, Cecilia AU - Kásler, Miklós AU - Müller, Veronika TI - Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients. Lessons from the Delta Variant TS - Lessons from the Delta Variant JF - VACCINES (BASEL) J2 - VACCINES-BASEL VL - 11 PY - 2023 IS - 12 PG - 12 SN - 2076-393X DO - 10.3390/vaccines11121786 UR - https://m2.mtmt.hu/api/publication/34411671 ID - 34411671 N1 - Funding Agency and Grant Number: Ministry of Human Resources of Hungary Funding text: The Center for Health Technology Assessment of the Semmelweis University participated in the project on a contractual basis with the Ministry of Human Resources of Hungary and received funding. AB - Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian COVID-19 registry was retrospectively investigated for risk of infection and hospitalization by time since the last vaccination, and vaccine effectiveness (VE) was calculated in adults with COPD diagnosis and an exact-matched control group during the Delta variant of concern (VOC) wave in Hungary (September–December 2021). For the matching, sex, age, major co-morbidities, vaccination status, and prior infection data were obtained on 23 August 2021. The study population included 373,962 cases divided into COPD patients (age: 66.67 ± 12.66) and a 1:1 matched group (age: 66.73 ± 12.67). In both groups, the female/male ratio was 52.2:47.7, respectively. Among the unvaccinated, there was no difference between groups in risk for infection or hospitalization. Regarding vaccinated cases, in the COPD group, a slightly faster decline in effectiveness was noted for hospitalization prevention, although in both groups, the vaccine lost its significant effect between 215 and 240 days after the last dose of vaccination. Based on a time-stratified multivariate Cox analysis of the vaccinated cases, the hazard was constantly higher in the COPD group, with an HR of 1.09 (95%: 1.05–1.14) for infection and 1.87 (95% CI: 1.59–2.19) for hospitalization. In our study, COPD patients displayed lower vaccine effectiveness against SARS-CoV-2 infection and hospitalization but a similar waning trajectory, as vaccines lost their preventive effect after 215 days. These data emphasize revaccination measures in the COPD patient population. LA - English DB - MTMT ER -